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ABSTRACT
Objectives: This study aims to examine the relationship of serum tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) levels with 
interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), fetuin-A, insulin, homeostatic model assessment (HOMA)-insulin resistance (IR), and disease 
activity in patients with rheumatoid arthritis (RA) who are in remission or have low disease activity.
Patients and methods: Fifty-four patients with RA (8 males, 46 females; mean age 52.7±12.3 years; range 40 to 64 years) and 34 healthy controls (6 
males, 28 females; mean age 53.2±11.3 years; range 41 to 65 years) were included in the study. The sTWEAK, fetuin-A, insulin, lipid profile and IL-6 
concentrations were determined. The HOMA-IR levels were calculated using a calculator. Disease activity score 28 was used to assess the disease 
activity.
Results: The erythrocyte sedimentation rate, C-reactive protein, fetuin-A, and IL-6 levels were higher in the RA group than in the control group 
(p=0.004, 0.001, 0.001, and 0.003, respectively). sTWEAK levels were lower in the RA group than in the control group (p=0.007). There were no 
differences in the TNF-α, HOMA-IR, insulin, and lipid profile levels of the two groups (p>0.05). sTWEAK had a negative correlation with body mass 
index and fetuin-A (r=-0.261 and r=-0.287, respectively).
Conclusion: We found that RA patients had lower sTWEAK levels and higher fetuin-A levels than the control group subjects. Furthermore, these 
two molecules were associated with each other. This study demonstrated that in RA patients, even if the disease is controlled with treatment, 
some molecules associated with an increased metabolic and cardiovascular risk continue to function. Follow-up studies on larger populations are 
warranted to confirm these findings.
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Rheumatic arthritis (RA) is a chronic disease 
of unknown etiology that causes the activation 
of pro-inflammatory pathways, leading to joint 
and systemic inflammations.1 The mortality in RA 
patients is increased by 0.9 to 3% compared to 
that in healthy individuals.2 Known metabolic and 
cardiovascular (CV) risk factors such as smoking 
and hyperlipidemia may have an influence in 
the development of CV diseases (CVDs), which 
are the main cause of mortality in patients with 
RA; however, lesser-known risk factors such 
as high inflammatory activity and autoimmune 
inflammatory factors may also play a role in these 
patients.2
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Tumor necrosis factor-alpha (TNF-a) is the 
first cytokine that was reported to be related 
to obesity and insulin resistance.3 Recently, 
TNF-like weak inducer of apoptosis (TWEAK) 
has drawn attention as a potential regulator 
of the inflammatory/anti-inflammatory balance 
in the developmental mechanism of insulin 
resistance.3 It has been reported to cause various 
biological effects through ligation (binding) with 
its receptor, fibroblast growth factor-inducible 
14 (Fn14). The biological effects of TWEAK 
also include the induction of pro-inflammatory 
cytokines, modulation of immune response and 
angiogenesis, stimulation of apoptosis, as well as 
tissue repair and regeneration.4,5 TWEAK induces 
the production of several pro-inflammatory 
molecules such as matrix metalloproteinase-1, 
interleukin (IL)-6, IL-8, monocyte chemoattractant 
protein-1 (MCP-1), and regulated upon activation 
of normal T cell expressed and secreted by the 
synoviocytes and fibroblasts, as well as intracellular 
adhesion molecule-1, E-selectin, IL-8, and MCP-1 
by the endothelial cells.6 The pro-inflammatory 
effects of TWEAK are observed in various cell 
types, including glomerular mesangial cells, 
human umbilical vascular endothelial cells, human 
gingival fibroblasts, human dermal fibroblasts, 
synoviocytes, chondrocytes, and fibroblasts.3,7-11 
Some authors have recommended the use of serum 
TWEAK (sTWEAK) as a potential biomarker in 
human metabolic and CV disorders.11 Few studies 
that have assessed the sTWEAK levels in RA 
have reported varying results.12-14 Fetuin-A (Alpha 
2-HS glycoprotein [g/L]) may qualify as a novel 
marker for the early detection of atherosclerosis. 
Recent data support the theory that the fatty 
liver/fetuin-A pathway plays an important role in 
regulating insulin sensitivity and may influence 
atherosclerosis in humans.15,16
According to our hypothesis, we speculate 
that the sTWEAK pathway is important in the 
pathogenesis of RA, and the metabolic disorders 
may continue to rise because of this pathway even 
if the RA disease activity decreases.
Therefore, in this study, we examined the 
relationship of serum sTWEAK levels with IL-6, 
TNF-a, fetuin-A, insulin, homeostatic model 
assessment (HOMA)-insulin resistance (IR), and 
disease activity in patients with RA who are in 
remission or have low disease activity.
PATIENTS AND METHODS
The study was designed as a single center, 
prospective, cross-sectional study at the 
rheumatology outpatient clinic of Sakarya University 
School of Medicine between December 2016 and 
March 2017. Blood samples were analyzed at 
the physiology laboratory by the department of 
physiology of our hospital. The study protocol 
was approved by the Sakarya University School 
of Medicine Ethics Committee. A written informed 
consent was obtained from each patient. The study 
was conducted in accordance with the principles of 
the Declaration of Helsinki.
Fifty four patients diagnosed with RA (8 males, 
46 females; mean age 52.7±12.3 years; range 
40 to 64 years) according to the 2010 American 
College of Rheumatology/European League 
Against Rheumatism classification criteria and 
34 healthy controls (6 males, 28 females; mean 
age 53.2±11.3 years; range 41 to 65 years) 
were included in the study. The patients were 
sequentially selected from the RA patients 
followed-up by the outpatient clinic. The subjects 
in the control group were selected from patient 
accompanists and patient visitors who do not have 
any diseases affecting the musculoskeletal system, 
and the two groups were matched with respect to 
age and sex. Age, sex, body mass index (BMI), 
educational status, disease duration, occupation, 
comorbidities, used drugs and demographic data 
were recorded for each patient.
Disease activity of the patients was assessed 
using the disease activity score 28 (DAS28). 
A score of DAS28 between 2.6-3.2 indicates low 
disease activity, 3.2-5.1 indicates moderate and 
>5.1 indicates high disease activity.16
Patients with diabetes mellitus, CVD, malignant 
hypertension, acute or chronic pancreatitis, with an 
inflammatory-auto-inflammatory disease other than 
RA, with hepatic and renal failure, diagnosed with a 
malignancy, who are pregnant or lactating, or below 
18 years of age were excluded from the study.
Blood samples from the patients and the 
control group were drawn into tubes without 
anticoagulant, allowed to completely clot at 
room temperature, then sera were separated by 
centrifuging at 4˚C at 5000 ¥ g for five minutes, 
and stored at -80˚C until the day of biochemical 
analyses.
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After the completion of the study groups, 
the sera were allowed to reduce to room 
temperature (20-25°C) to prepare them for 
biochemical analyses. To determine the serum 
IL-6, TNF-a, insulin, fetuin-A and TWEAK levels, 
commercial kits following the kit protocols were 
used, and solid phase sandwich enzyme linked 
immunosorbent assay (ELISA) method (Biotek 
ELX50 Reader Instruments, Winooski, VT, USA 
and Biotek ELX-800 Washer, USA) was applied. 
For serum IL-6 (eBioscience Platinum ELISA, 
Catalog No: BMS213/2; Bender Medsystems 
GmbH, Vienna, Austria), IL-6 standards with 
known concentration and serum samples were 
placed into ELISA plates coated with human 
IL-6 specific monoclonal antibodies. Following 
the incubation, elimination and color reaction 
phases, color change was observed, evaluated by 
measurement and expressed in pg/mL. Similar 
procedures were applied for serum insulin levels 
(DRG insulin ELISA Enzyme Immunosorbent 
Test Kit, EIA-2935, DRG Instruments GmbH, 
Global Heda quarters, Marburg, Germany), 
serum TWEAK levels (Human TWEAK Instant 
ELISA kit, BMS2006 INST, eBioscience 
Bender MedSystems GmbH, Vienna, Austria), 
serum TNF-a levels (eBioscience, TNF-Alpha 
Platinum ELISA, Catalog No: (BMS223/4TEN, 
eBioscience Bender MedSystems GmbH, 
Vienna, Austria) and serum fetuin-A levels 
(AssayPro, Catalog No: EG3501-1, Assaypro 
LLC, USA). All biomarker samples were read 
on the ELISA reader (ELISA instrument brand 
model, (Biotek ELX50 Reader Instruments, 
Winooski, VT, USA and Biotek ELX-800 
Washer, USA) at 450 nm wavelength. The 
results were expressed in pg/mL taking into 
consideration the given sensitivity values and 
calculating from the standard curve.
Statistical analysis
Expert support was obtained for the statistical 
analysis of the article. The Number Cruncher 
Statistical System 2007 (Kaysville, Utah, USA) 
software was used for the statistical analyses. 
Between-group comparisons were performed 
using the Student’s t-test, Mann-Whitney 
U test, and Pearson’s chi-square test. Spearman 
correlation coefficient was used for correlation 
analysis. Values of p<0.01 and p<0.05 were 
considered statistically significant.
Table 1. Comparison of patient and control groups according to study parameters
Rheumatoid arthritis (n=54) Healthy subjects (n=34)
n Mean±SD n Mean±SD p value









Fasting glucose (mg/dL) 98.4±20.0 94.2±6.2 0.166
Triglyceride (mg/dL) 129.0±72.4 110.4±24.9 0.131
Total cholesterol (mg/dL) 206.7±32.5 212.2±25.5 0.476
High-density lipoprotein cholesterol (mg/dL) 54.3±11.1 50.9±3.7 0.071
Low-density lipoprotein cholesterol (mg/dL) 120.1±25.3 111.9±11.8 0.080
C-reactive protein (mg/L) 10.6±11.5 4.0±1.2 0.001*
Erythrocyte sedimentation rate (mm/hour) 30.4±18.2 22.6±4.2 0.004*
sTWEAK (pg/mL) 1051.4±439.2 1277.1±323.1 0.007*
Tumor necrosis factor-alpha (pg/mL) 17.9±7.5 17.1±2.1 0.471
Insulin (μIU/mL) 22.4±19.1 19.1±15.4 0.378
Homeostasis model assessment of insulin resistance 6.0±6.7 4.4±3.3 0.124
Fetuin-A (g/L) 939±7.7 1.5±4.3 0.001*
Interleukin-6 (pg/mL) 6.7±10.7 2.1±1.0 0.003*




There were no statistically significant 
differences between the patient and control 
groups in terms of sex, age and BMI (p>0.05). 
The main demographic, clinical and laboratory 
characteristics of the groups are summarized in 
Table 1.
Of the RA patients included in the study, 
34 (62%) were receiving synthetic disease 
modifying antirheumatic drugs therapy and 
43 (79.6%) were receiving low-dose steroid 
therapy. Sixteen patients (29%) were receiving 
TNF blocker therapy, two (3%) were receiving IL-6 
inhibitor therapy, and two (3%) were receiving 
rituximab therapy. The mean steroid cumulative 
dose was 2.9±25.65 for 50 patients.
The mean DAS28 score for the RA patients 
was 2.7±0.94. According to DAS28, 38 patients 
had low disease activity (2.6<DAS28<3.2) and 
16 were in remission (2.6<DAS28). None of the 
patients had moderate or high disease activity. 
When the RA patients were grouped according 
to their DAS28 scores, no significant difference 
was found between the groups in terms of the 
laboratory parameters (p>0.05) (Table 2).
Correlations of the laboratory parameters with 
some demographic characteristics and clinical 
parameters are shown in Table 3. A significant 
positive correlation was found between the IL-6 
concentrations and TNF-a (r=0.453, p=0.001). 
Significant correlations were detected of fetuin-A 
concentration with disease duration and total 
cholesterol (positive) and with sTWEAK (negative).
DISCUSSION
It is noteworthy that while the sTWEAK 
levels were lower in the RA group than in the 
Table 2. Comparison of biochemical parameters between groups in patients with rheumatoid arthritis 
according to disease activity score 28
Low disease activity 
group (n=38)
Group in remission group
(n=16)
Mean±SD Mean±SD p value
Tumor necrosis factor-alpha (pg/mL) 18.4±9.0 16.6±1.7 0.245
Insulin (μIU/mL) 12.8±4.0 11.7±3.2 0.644
Homeostasis model assessment of insulin resistance 6.1±7.4 5.9±5.2 0.894
sTWEAK (pg/mL) 1039.5±387.8 1077.4±547.3 0.799
Fetuin-A (g/L) 986.6±7.7 836.1±7.9 0.514
Interleukin-6 (pg/mL) 5.4±7.6 9.6±15.4 0.291
SD: Standard deviation; sTWEAK: Serum TNF-like weak inducer of apoptosis; Fetuin-A: Alpha 2-HS glycoprotein.
Table 3. Correlation of laboratory parameters with clinical parameters
 CRP ESR Insulin HOMA-IR sTWEAK IL-6 Fetuin-A
Diagnosis duration 0.031 -0.096 -0.167 -0.126 -0.051 0.006 0.302
Body mass index 0.123 0.015 0.112 0.177 -0.261 0.047 0.053
Total cholesterol 0.203 -0.034 0.286* 0.343* 0.043 0.187 0.249*
Tumor necrosis factor-alpha 0.090 0.169 0.030 0.037 0.024 0.453* 0.138
Disease activity score 28 scores 0.517** 0.329* 0.229 0.163 0.006 0.157 0.026
sTWEAK 0.158 0.181 0.104 -0.241 - -0.108 -0.287*
CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; HOMA-IR: Homeostasis model assessment of insulin resistance; sTWEAK: Serum tumor 
necrosis factor-like weak inducer of apoptosis; IL-6: Interleukin-6; Fetuin-A: Alpha 2-HS glycoprotein; * Spearman correlation. Values are shown as correlation 
coefficients (r); bold values indicate statistically significant values. Correlation is significant at the 0.05 level (2-tailed); **Correlation is significant at the 0.01 
level (2-tailed).
75Metabolic and Inflammatory Alternations in Patients With Rheumatoid Arthritis
control group and the serum IL-6 and fetuin-A 
levels were significantly higher in the RA group, 
the TNF-a, insulin, and HOMA-IR levels were 
similar between the two groups. Moreover, 
sTWEAK levels had a poor correlation with BMI 
and fetuin-A levels.
Disturbance in the homeostasis of the pro-
inflammatory and anti-inflammatory systems plays 
an important role in the etiology of metabolic 
diseases. This could be because pro-inflammatory 
cytokines and metabolic abnormalities associated 
with systemic inflammation play a vital role in 
the mechanism leading to inflammation in RA 
patients.17,18
Serum tumor necrosis factor-like weak 
inducer of apoptosis is a molecule involved in the 
apoptosis, proliferation, and migration phases 
of cells. Studies have shown that sTWEAK 
treatment increases cell proliferation in some 
cell types such as vascular endothelial cells and 
smooth muscle cells, and this effect is similar 
to the effect of the vascular endothelial growth 
factor, a strong angiogenic-mitogenic factor.19 
In chronic inflammatory conditions such as RA, 
TWEAK may be more harmful at the endothelial 
level due to this effect. While some studies 
show that increased TWEAK levels indicate 
vascular damage, indirect evidence suggests that 
TWEAK may contribute to the development 
of atherosclerosis in inflammatory or metabolic 
diseases by increasing endothelin synthesis.20
Recent studies on the pathogenesis of 
RA have drawn attention to the sTWEAK/
Fn14 pathway. TWEAK is a member of the 
TNF superfamily that is structurally related to 
cytokines and is a protein that exhibits cytotoxic 
and pro-inflammatory activities.10 Recent 
in vivo studies have demonstrated that the 
blockage of TWEAK activity by neutralization 
of the anti-TWEAK antibodies causes significant 
reductions in the clinical response and synovial 
inflammation in collagen-induced arthritis.21,22 
Following the detection of increased levels of 
the sTWEAK molecule in the synovia and the 
serum in mice arthritis model studies, in vitro 
studies were conducted. TWEAK, which acts 
as a pro-inflammatory and pro-angiogenic 
mediator, was found to have a strong relationship 
with rheumatoid synovitis. Chicheportiche et 
al.10 demonstrated that TWEAK induces the 
production of pro-inflammatory cytokines and 
chemokines by the normal human dermal 
fibroblasts and synoviocytes obtained from 
RA patients. Under physiological conditions, 
TWEAK may contribute to tissue repair and 
regeneration after acute damage by binding 
to its receptor Fn14. In chronic inflammatory 
conditions, the TWEAK/Fn14 pathway increases 
chronic inflammation, pathological hyperplasia, 
and angiogenesis.23 It has been suggested that 
in order for TWEAK to induce angiogenesis, the 
TWEAK/Fn14 pathway should be blocked.24
Park et al.13 found a correlation between 
significantly increased sTWEAK levels and disease 
activity in RA patients. In contrast, unlike other 
studies, the research by Karkucak et al.12 showed 
no significant difference in the serum TWEAK 
levels of RA patients and healthy controls; this 
finding was attributed to the fact that about 50% 
of the RA patients in this study were receiving 
TNF blocker therapy, a type of therapy known to 
lower sTWEAK levels. Park et al.13 demonstrated 
that sTWEAK levels significantly reduce following 
TNF blocker therapy in RA patients. In our study, 
we investigated the molecules involved in RA and 
the metabolic damage they cause. We therefore 
enrolled RA patients who were in remission or 
had low disease activity. Majority of the patients 
in the study were being administered biological 
agents.
Rheumatoid arthritis not only causes the 
destruction of the cartilage and bone but also 
damages the metabolic and endocrine systems. 
This demonstrates a relationship between the 
inflammatory factors, insulin resistance, and 
metabolic syndrome.25 Many different mechanisms 
related to increased CVD risk in RA were 
investigated. Physical inactivity, hypertension, 
diabetes, and obesity are associated with 
atherosclerosis in RA; however, the evidence for 
these risk factors is insufficient. Therefore, it is not 
possible to explain RA-associated atherosclerosis 
with only the known risk factors.2
Lower sTWEAK levels were observed in 
atherosclerosis patients and circulating sTWEAK 
levels were negatively correlated to the 
intima/media thickness in asymptomatic patients; 
therefore, it can be concluded that sTWEAK 
levels are low in many CVD indications.26-29 
Consistent with these findings, low sTWEAK 
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levels were also observed in the peripheral 
blood samples of obese individuals.29 sTWEAK 
levels were negatively correlated with glucose 
and glycosylated hemoglobin A1c levels as well 
as with HOMA-IR and abdominal obesity; this 
supports the hypothesis that low sTWEAK levels 
are associated with a poor CV profile. sTWEAK 
prevents TNF-a-induced insulin resistance by 
activating the protein phosphatase 2A pathway 
in human adipocytes.30 All these molecules are 
among the known CV risk factors.31-33 Moreover, 
the observed lower release of sTWEAK in carotid 
atheroma plaques compared to that in normal 
arteries supports an association between the 
lipotoxic effects of abnormal lipid accumulation 
and TWEAK synthesis.24 In our study, we found 
that the sTWEAK levels of the RA group that 
comprised patients who were in remission or 
had low disease activity were lower than those 
of the control group. sTWEAK had a weak 
positive correlation with BMI and a weak negative 
correlation with fetuin-A levels. Previous studies 
have demonstrated an inverse correlation between 
increased CVD risk and sTWEAK levels.31-33 The 
low sTWEAK levels found in RA patients suggest 
that because of the nature of the diseases, risk 
of CVD and subclinical atherosclerosis may exist 
even if RA subsides.
Lower levels of sTWEAK than those of other 
cytokines have a protective effect against the 
risk of CVDs associated with a high chronic 
inflammatory activity; however, the underlying 
mechanism for this is not clearly understood. 
Some hypotheses were suggested to explain this. 
One hypothesis suggests that serum sTWEAK 
levels decrease because of binding to the Fn14 
receptor. An alternative hypothesis stated the 
cause as the increase in sCD163 and decrease in 
sTWEAK in carotid atheroma plaques.34
Another molecule that has recently 
been demonstrated to be associated with 
atherosclerosis is fetuin-A. Fetuin-A, a protein 
secreted primarily by the liver, has been 
associated with subclinical markers of CVD, 
insulin resistance, type 2 diabetes, and 
incidence of total CVD, particularly ischemic 
stroke.34-39 However, the concentrations at 
which fetuin-A has a deleterious effect have not 
been identified. Several studies have reported 
contradictory results regarding the role of 
fetuin-A in rheumatologic diseases. Sato et al.38 
reported decreased levels of fetuin-A in patients 
with RA. Biswas et al.39 reported that RA 
patients had significantly higher fetuin-A 
levels in the synovial fluid than the healthy 
controls. Tekeoglu et al.40 found higher fetuin-A 
levels in RA patients than in healthy controls. 
Furthermore, in our study, the RA group had 
higher fetuin-A levels than the control group; 
however, the sTWEAK levels were lower in the 
RA group. A significant negative correlation 
was found between fetuin-A and sTWEAK 
levels. This result is in line with the established 
association of increased fetuin-A levels and 
decreased sTWEAK levels with CVD risk that 
is known to be increased in RA.
Our study has some limitations. First, we 
did not quantify the subclinical atherosclerosis. 
Moreover, data were collected using a cross-
sectional research design. We excluded the RA 
patients with high disease activity from the 
study. We could have included such a group and 
investigated its relationship with the group of RA 
patients with low disease activity.
In conclusion, the main purpose of this study 
was to investigate, using some current molecules, 
whether metabolic risk persists in RA patients 
with low disease activity who are undergoing 
treatment. We found lower sTWEAK levels and 
higher fetuin-A levels in RA patients compared 
to those in the controls. We also observed that 
these two molecules are associated with each 
other. We demonstrated that in RA patients, some 
molecules associated with increased metabolic and 
cardiovascular risk continue to pose a risk even if 
the disease is controlled with treatment. Follow-
up studies on larger populations are warranted to 
confirm our findings.
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